|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
EP4098278A1
(en)
|
2014-11-13 |
2022-12-07 |
The Johns Hopkins University |
Checkpoint blockade and microsatellite instability
|
|
MA40737A
(fr)
*
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
US20180133327A1
(en)
*
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
CA2988388C
(en)
*
|
2015-04-23 |
2022-11-22 |
Nantomics, Llc |
Cancer neoepitopes
|
|
SG10201912485PA
(en)
|
2015-05-13 |
2020-02-27 |
Agenus Inc |
Vaccines for treatment and prevention of cancer
|
|
GB201516047D0
(en)
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
CA3003251A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
|
|
AU2016339924B2
(en)
*
|
2015-10-12 |
2020-01-02 |
Nantomics, Llc |
Compositions and methods for viral cancer neoepitopes
|
|
US10339274B2
(en)
*
|
2015-10-12 |
2019-07-02 |
Nantomics, Llc |
Viral neoepitopes and uses thereof
|
|
EP3365000B1
(en)
*
|
2015-10-23 |
2020-06-10 |
Novartis AG |
Method of deriving a value for percent biomarker positivity for selected cells present in a field of view
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
RU2729116C2
(ru)
|
2015-12-16 |
2020-08-04 |
Гритстоун Онколоджи, Инк. |
Идентификация, производство и применение неоантигенов
|
|
WO2017118702A1
(en)
*
|
2016-01-08 |
2017-07-13 |
Vaccibody As |
Neoepitope rna cancer vaccine
|
|
US11585805B2
(en)
|
2016-02-19 |
2023-02-21 |
Nantcell, Inc. |
Methods of immunogenic modulation
|
|
CA3015913A1
(en)
*
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
EP3431595A4
(en)
*
|
2016-03-15 |
2019-11-20 |
Repertoire Genesis Incorporation |
MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS
|
|
DK3429618T5
(da)
*
|
2016-03-16 |
2024-09-16 |
Amal Therapeutics Sa |
Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin
|
|
SG11201810951RA
(en)
*
|
2016-06-10 |
2019-01-30 |
Io Therapeutics Inc |
Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
|
|
WO2018005276A1
(en)
*
|
2016-06-29 |
2018-01-04 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
DK3515476T3
(da)
|
2016-09-21 |
2024-09-02 |
Amal Therapeutics Sa |
Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer
|
|
US11332530B2
(en)
|
2016-09-23 |
2022-05-17 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
AU2017339517B2
(en)
*
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
CA3045811A1
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
US11480572B2
(en)
|
2016-12-16 |
2022-10-25 |
Nantbio, Inc. |
Live cell imaging systems and methods to validate triggering of immune response
|
|
WO2018132753A1
(en)
*
|
2017-01-13 |
2018-07-19 |
Nantbio, Inc. |
Validation of neoepitope-based treatment
|
|
WO2018136664A1
(en)
|
2017-01-18 |
2018-07-26 |
Ichan School Of Medicine At Mount Sinai |
Neoantigens and uses thereof for treating cancer
|
|
WO2018146128A1
(en)
*
|
2017-02-07 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
|
|
US20200102618A1
(en)
*
|
2017-03-17 |
2020-04-02 |
Nantomics, Llc |
LIQUID BIOPSY FOR cfRNA
|
|
KR102775647B1
(ko)
*
|
2017-03-31 |
2025-03-06 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
US12072337B2
(en)
|
2017-05-30 |
2024-08-27 |
Nant Holdings Ip, Llc |
Circulating tumor cell enrichment using neoepitopes
|
|
US20200276285A1
(en)
|
2017-06-02 |
2020-09-03 |
Arizona Board Of Regents On Behalf Of Arizona State University |
A method to create personalized cancer vaccines
|
|
EP3879535B1
(en)
*
|
2017-06-13 |
2024-12-11 |
BostonGene Corporation |
Systems and methods for identifying cancer treatments from normalized biomarker scores
|
|
GB201710815D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Francis Crick Inst Ltd |
Method
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
MX2020003204A
(es)
|
2017-09-20 |
2020-07-20 |
Regeneron Pharma |
Metodos de inmunoterapia para pacientes cuyos tumores portan una carga mutacional alta de un gen pasajero.
|
|
EP3688165A4
(en)
|
2017-09-25 |
2021-09-29 |
Nant Holdings IP, LLC |
VALIDATION OF THE PRESENTATION OF NEOEPITOPES
|
|
CN117987553A
(zh)
*
|
2017-09-25 |
2024-05-07 |
纪念斯隆凯特琳癌症中心 |
肿瘤突变负荷和检查点免疫疗法
|
|
KR20260039788A
(ko)
|
2017-10-10 |
2026-03-20 |
시애틀 프로젝트 코포레이션 |
핫스팟을 이용한 신생항원 동정
|
|
US20200239577A1
(en)
|
2017-10-15 |
2020-07-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3704268B1
(en)
|
2017-11-03 |
2025-01-22 |
Guardant Health, Inc. |
Normalizing tumor mutation burden
|
|
WO2019094692A2
(en)
*
|
2017-11-09 |
2019-05-16 |
The Trustees Of The University Of Pennsylvania |
Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
|
|
CA3083097A1
(en)
|
2017-11-22 |
2019-05-31 |
Gritstone Oncology, Inc. |
Reducing junction epitope presentation for neoantigens
|
|
EP3622522A1
(en)
|
2017-12-01 |
2020-03-18 |
Illumina, Inc. |
Methods and systems for determining somatic mutation clonality
|
|
CN108009400B
(zh)
*
|
2018-01-11 |
2018-07-06 |
至本医疗科技（上海）有限公司 |
全基因组肿瘤突变负荷预测方法、设备以及存储介质
|
|
US11414698B2
(en)
*
|
2018-03-22 |
2022-08-16 |
Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi |
Method of quantifying mutant allele burden of target gene
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
JP7466519B2
(ja)
|
2018-07-23 |
2024-04-12 |
ガーダント ヘルス， インコーポレイテッド |
腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム
|
|
JP7539367B2
(ja)
|
2018-08-31 |
2024-08-23 |
ガーダント ヘルス， インコーポレイテッド |
無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
|
|
CN109371005B
(zh)
*
|
2018-11-12 |
2022-09-30 |
上海市东方医院（同济大学附属东方医院） |
一种hla-0201限制性padi4表位多肽及其应用
|
|
CN113194995A
(zh)
*
|
2018-12-12 |
2021-07-30 |
免疫医疗有限责任公司 |
基于血液的肿瘤突变负荷预测非小细胞肺癌的总存活
|
|
US20220081723A1
(en)
*
|
2018-12-21 |
2022-03-17 |
Agency For Science, Technology And Research |
Method of predicting for benefit from immune checkpoint inhibition therapy
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
EP3947739A1
(en)
|
2019-04-05 |
2022-02-09 |
Illumina, Inc. |
Quantitative score of hla diversity
|
|
WO2020242837A1
(en)
*
|
2019-05-24 |
2020-12-03 |
Iuve, Inc. |
A precision medicine method for cancer immunotherapy
|
|
EP4038222A4
(en)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
NL2024107B1
(en)
*
|
2019-10-26 |
2021-07-19 |
Vitroscan B V |
Compositions for Patient Specific Immunotherapy
|
|
CN111088349B
(zh)
*
|
2020-02-14 |
2023-04-28 |
深圳市宝安区妇幼保健院 |
Kir3dl1基因分型引物组及其应用
|
|
WO2021190983A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Koninklijke Philips N.V. |
Prediction of radiotherapy response for prostate cancer subject based on immune checkpoint genes
|
|
GB202007099D0
(en)
|
2020-05-14 |
2020-07-01 |
Kymab Ltd |
Tumour biomarkers for immunotherapy
|
|
US12295997B2
(en)
|
2020-07-06 |
2025-05-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4000595A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
EP4000596A1
(en)
*
|
2020-11-17 |
2022-05-25 |
The Boots Company plc |
Tetrapeptide and compositions comprising tetrapeptides
|
|
WO2022217136A1
(en)
*
|
2021-04-10 |
2022-10-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
A multiomic approach to modeling of gene regulatory networks in multiple myeloma
|
|
JP2024534120A
(ja)
|
2021-08-24 |
2024-09-18 |
ビオンテック・ソシエタス・エウロパエア |
インビトロ転写技術
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
EP4695807A1
(en)
|
2023-04-12 |
2026-02-18 |
Icahn School of Medicine at Mount Sinai |
Computational methods for selecting personalized neoantigen vaccines
|